Extended-spectrum β-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy by Meier, S. et al.
CLINICAL AND EPIDEMIOLOGICAL STUDY
Extended-spectrum b-lactamase-producing Gram-negative
pathogens in community-acquired urinary tract infections:
an increasing challenge for antimicrobial therapy
S. Meier • R. Weber • R. Zbinden • C. Ruef •
B. Hasse
Received: 7 April 2011 / Accepted: 7 June 2011 / Published online: 25 June 2011
 Springer-Verlag 2011
Abstract
Background Extended-spectrum b-lactamases (ESBLs)
are an increasing challenge in the treatment of urinary tract
infections (UTIs), and also in the community. We aimed to
investigate the characteristics of patients with UTIs due to
ESBL-producing Escherichia coli and to assess the risk
factors for ESBLs in community-acquired isolates.
Methods We performed a retrospective study from Jan-
uary 1, 2007 to December 31, 2009 at a tertiary care
teaching hospital in Switzerland, comparing patients with
community-acquired versus healthcare-associated UTIs
due to ESBL-producing E. coli. Additionally, we investi-
gated the antimicrobial susceptibility of these isolates.
Results A total of 123 patients were studied, of whom 79
(64%) had community-acquired and 44 (36%) had health-
care-associated UTIs. Community-acquired isolates were
associated with acute uncomplicated UTIs (odds ratio [OR]
6.62, 95% confidence interval [CI] 1.83–36.5, P \ 0.001).
Risk factors were recurrent UTI (OR 3.04, 95% CI
1.14–9.14, P = 0.022) and female sex (OR 2.46, 95% CI
1.01–6.08). Community-acquired ESBL-producing E. coli
urinary isolates showed high resistance rates to most of the
currently used oral antimicrobial agents, including b-lac-
tam antibiotics (amoxicillin–clavulanic acid, 69.6% resis-
tance), quinolones (ciprofloxacin, 84.8% resistance;
norfloxacin, 83.9% resistance), and trimethoprim–sulfa-
methoxazole (75.9% resistance), except for nitrofurantoin
(15% resistance) and fosfomycin (0% resistance).
Conclusion UTI due to ESBL-producing E. coli are
emerging, and also in a country with low antibiotic use.
Because of increasing antibiotic resistance rates of E. coli
to current standard therapy and because of the resistance
patterns of ESBL-producing E. coli, guidelines for the
management of UTIs must be revised. Fosfomycin or
nitrofurantoin are recommended for the first-line empirical
oral treatment of community-acquired uncomplicated
UTIs.
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Introduction
Frequent or inappropriate use of antibiotics in humans and
animals led to an increasing resistance rate of Gram-neg-
ative bacteria in recent years. Consequently, the treatment
of urinary tract infections (UTIs) has become more com-
plex, not only because of an increasing bacterial resistance
to fluoroquinolones, trimethoprim–sulfamethoxazole, or
other standard antibiotics [1, 2], but also because of the
emergence of extended-spectrum b-lactamases (ESBLs) in
Enterobacteriaceae [3–6]. ESBLs are b-lactamases which
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confer bacterial resistance to b-lactam antibiotics and
aztreonam [7]. Escherichia coli are the most common
cause of acute uncomplicated UTI, and reports of com-
munity-acquired UTI with ESBL-producing E. coli have
accumulated in recent years [8–10].
The identification of risk factors for antimicrobial
resistance may contribute to the improved empirical
treatment of UTIs. Reported risk factors for developing a
UTI with a community-acquired ESBL-producing E. coli
are older age, female sex, diabetes mellitus, recurrent UTI,
invasive urological procedures, and prior use of antibiotics
such as aminopenicillins, cephalosporins, or fluoroquino-
lones [9, 11–15]. In a recent case–control study about risk
factors for infections with ESBL-producing E. coli and
Klebsiella pneumoniae, we observed ten patients with non-
healthcare-associated UTIs due to ESBL-producing E. coli
in the time period from July 2005 to June 2007 [16]. The
aim of the present study was to continue the surveillance of
these pathogens at our institution, to characterize patients
with urinary samples positive for ESBL-producing E. coli,
to identify risk factors for community-acquired UTIs, and
to assess antibiotic resistance patterns.
Methods
Setting
This is a retrospective study conducted at the University
Hospital in Zurich, Switzerland, a tertiary care teaching
hospital. The computerized database of the Institute of
Medical Microbiology, University of Zurich, where all
microbiological samples of the University Hospital are
processed, was used to identify patients with the detection
of ESBL-producing E. coli ([104 colony forming units per
milliliter) in urinary samples from January 1, 2007 to
December 31, 2009.
Data collection and definitions
Clinical data from outpatients and inpatients of the
Departments of Urology, Gynaecology/Obstetrics, and
Internal Medicine were retrieved from patient charts.
Women were classified to have acute uncomplicated UTI if
they had a structurally normal urinary tract and symptoms
of cystitis. If women had an infection of the renal pelvis
without structural anomalies, they were classified to have
acute uncomplicated pyelonephritis. Men with UTIs in the
setting of a structurally normal urinary tract were assigned
to have complicated UTI. All patients with structural
abnormalities and signs of symptomatic cystitis or pyelo-
nephritis were assigned to have complicated UTI.
Asymptomatic patients with positive urine cultures (also
those with an indwelling catheter) were classified as having
asymptomatic bacteriuria. Infections were rated as com-
munity-acquired if they did not fulfill any of the following
criteria: (1) patient received intravenous therapy or spe-
cialized wound care at home; (2) patient received hemod-
ialysis treatment or antineoplastic chemotherapy in the
30 days before the infection; (3) patient was hospitalized in
an acute care center 2 days in the 90 days before infection;
(4) patient resided in a nursing home or long-term care
facility [17].
A structured questionnaire was used to collect the
following variables: age, gender, clinical symptoms of
UTI, previous urological operations, obstructive diseases
of the urinary tract, history of recurrent UTI, hospital-
izations in the previous year (and the reasons for the
hospitalization), residency in a nursing home, antibiotic
treatment during the previous year, and immunosuppres-
sive medication (including steroids). The severity of
comorbidity was assessed using the Charlson comorbidity
index [18].
Microbiological analysis
Antimicrobial susceptibility testing and screening for ES-
BLs was performed according to the Clinical and Labora-
tory Standards Institute (CLSI) recommendations. In brief,
the initial screen test to indicate ESBL production was a
diameter of the inhibition zone of ceftazidime B22 mm or
of cefotaxime B27 mm. Furthermore, any synergy between
amoxicillin–clavulanic acid and ceftazidime or cefepime
(double-disk method) or between piperacillin–tazobactam
and cefotaxime in the disk diffusion test was also an
indication for the organism to be tested by a phenotypic
confirmatory test. A greater than twofold concentration
decrease in the minimum inhibitory concentration (MIC)
for ceftazidime or cefepime or cefotaxime tested in com-
bination with clavulanic acid versus its MIC when tested
alone was confirmatory for ESBL production. In accor-
dance with the CLSI 2008 guidelines, all ESBL-producing
E. coli strains were classified as resistant to all penicillins,
cephalosporins, and aztreonam, regardless of the MICs
determined for these drugs [19].
Statistical analysis
We used EpiData (version 3.1, Jan 2008) for the statistical
analyses. Categorical data were analyzed using the Fisher’s
exact test and continuous data were analyzed by the
Kruskal–Wallis test. We used logistic regression analyses
for the univariable calculation of risk factors and odds
ratios (OR) with 95% confidence intervals (CI). A two-
tailed test of significance with a P-value \0.05 was con-
sidered to be statistically significant.
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Ethical approval
Approval by the Research Ethics Board of the Canton of
Zurich, Switzerland (address: Kantonale Ethikkommission
Zu¨rich, Sonneggstrasse 12, CH-8091 Zu¨rich, Switzerland),
was obtained. The ethics committee decided that patients’
informed consent was not required because this study was a
retrospective quality control project by infectious diseases
physicians directly involved in patient care.
Results
In the reference period, 5,694 urine samples were positive
for E. coli, and, among those, 123 (2.16%) were ESBL-
producers. A total of 40 patients were treated in the
Department of Urology, 51 patients in the Department of
Internal Medicine, and 32 in the Department of Gynae-
cology/Obstetrics.
Patient characteristics
The characteristics of the 123 patients with ESBL-pro-
ducing E. coli UTIs are shown in Table 1. The median age
was 48 years (interquartile range [IQR] 34–68 years).
Seventy-nine (64.3%) patients had a community-acquired
and 44 (35.8%) a healthcare-associated infection. Of 79
patients with community-acquired infections 63 (79.7%)
patients and 27/44 (61.4%) patients with healthcare-asso-
ciated infections were female. Comorbidities were equally
distributed in both groups, except for non-urological
malignancies (1.3 vs. 11.4%, P = 0.022). Previous hospi-
talizations in the preceding year was noted in 36 (45.6%)
patients with community-acquired infection and in 32
Table 1 Baseline
characteristics and clinical
presentation of 123 individuals
with extended-spectrum b-
lactamase (ESBL)-producing
Escherichia coli in urinary
samples, stratified by the
location of acquisition
UTI urinary tract infection
Characteristics Community-acquired
UTI
Healthcare-associated
UTI
P-value
Number of patients (%) 79 (100) 44 (100)
Female, n (%) 63 (79.7) 27 (61.4) 0.035
Age (years), median (IQR) 48 (33–66) 52 (37–70) 0.284
Resident in a nursing home, n (%) 0 (0) 6 (13.6) –
Hospital stay in the previous year, n (%) 36 (45.6) 32 (72.7) 0.002
Intensive care stay in the previous year, n (%) 8 (10.1) 2 (4.6) 0.492
Charlson comorbidity index (IQR) 0 (0–1) 0 (0–2) 0.009
Comorbidities, n (%)
Renal insufficiency 10 (12.8) 10 (22.7) 0.203
Diabetes mellitus 8 (10.1) 8 (18.2) 0.264
Immunosuppression 12 (15.2) 8 (18.2) 0.799
Non-urological neoplasia 1 (1.3) 5 (11.4) 0.022
Antibiotic use in the previous year, n (%) 52 (65.8) 28 (63.6) 0.845
Duration of antibiotic treatment (days),
median (IQR)
3 (0–11) 1 (0–19.5) 0.837
Urological history and morbidity, n (%)
Previous urological operations 23 (29.1) 18 (40.9) 0.232
Anomaly of the urinary tract 32 (40.5) 28 (63.6) 0.016
Prostata hyperplasia 4 (5.1) 1 (2.3) 0.654
Urolithiasis 1 (1.3) 4 (9.1) 0.055
Ureteral stenosis 1 (1.3) 4 (9.1) 0.055
Urological neoplasia 1 (1.3) 3 (6.8) 0.130
Incontinence 10 (12.7) 7 (15.9) 0.599
Neurological impairment of the bladder 7 (8.9) 6 (13.6) 0.542
Self-catheterism 2 (2.5) 5 (11.4) 0.100
Foreign material in the urinary tract 4 (5.1) 15 (34.1) \0.001
Clinical presentation, n (%)
Asymptomatic bacteriuria 24 (30.4) 25 (56.8) 0.007
Uncomplicated lower UTI 26 (32.9) 3 (6.8) \0.001
Uncomplicated upper UTI 5 (6.3) 3 (6.8) 1.000
Complicated UTI 24 (30.4) 13 (29.5) 1.000
Community-acquired ESBL-producing E. coli urinary tract infections 335
123
(72.7%) healthcare-associated UTIs. Urinary tract anoma-
lies (63.6 vs. 40.5%, P = 0.016) and foreign material in the
urinary tract (34.1 vs. 5.1%, P \ 0.001) were found more
frequently in patients with healthcare-associated infections,
and there was also a trend for a higher rate of urolithiasis
(9.1 vs. 1.3%, P = 0.055) and ureteral stenosis (9.1 vs.
1.3%, P = 0.055). Patients with community-acquired
infections presented more frequently with uncomplicated
lower UTI (32.9 vs. 6.8%, P \ 0.001), whereas patients
with healthcare-associated infections more likely had
asymptomatic bacteriuria (30.4 vs. 56.8%, P = 0.007).
Empirical antimicrobial therapy
A proportion of 90/123 patients received antibiotic
prescriptions. For empirical antibiotic therapy, quinolones
were used in 44 of 90 (48.8%) patients, penicillins in 25.5%,
cephalosporins in 5.6%, carbapenems in 12.2%, and
trimethoprim–sulfamethoxazole in 10.0%. Community-
acquired UTIs were treated empirically with quinolones
(31/55 prescriptions, 56.3%), penicillins (29.1%), or
trimethoprim–sulfamethoxazole (14.5%). Empirical treat-
ment with nitrofurantoin was prescribed in 2 (3.6%) and
with fosfomycin in 1.5% of cases.
Acute uncomplicated UTI
All of the 26 patients presenting with acute uncomplicated
UTI caused by community-acquired ESBL-producing
E. coli isolates were women. The median age was 38 years
(IQR 17–80) and the median Charlson comorbidity index
was 0 (0–1). Three patients (11.5%) had been hospitalized
in the previous years (one patient received mechanical
ventilation), none had indwelling urological foreign mate-
rial, and 9/26 (34.6%) experienced recurrent UTI. A pro-
portion of 11/26 (42.3%) had received antibiotic treatment,
of whom eight had received fluoroquinolones, one amoxi-
cillin–clavulanic acid, and two trimethoprim–sulfameth-
oxazole. Of the 26 ESBL-producing E. coli urinary isolates
from acute uncomplicated UTI, 20 (76.9%) were resistant
to ciprofloxacin, 69.2% to norfloxacin, 57.7% to amoxi-
cillin–clavulanic acid, and 69.2% to trimethoprim–sulfa-
methoxazole. All isolates were susceptible to
nitrofurantoin, fosfomycin, and ertapenem.
Risks for ESBL-producing E. coli
in community-acquired UTI
Univariable analyses of risk factors for ESBL-producing
E. coli in community-acquired UTI are shown in Table 2.
There was an association of community-acquired isolates
with acute uncomplicated UTI (OR 6.62, 95% CI
1.83–36.5, P \ 0.001), recurrent UTI (OR 3.04, 95%
CI 1.14–9.14, P = 0.022), and female sex (OR 2.46, 95%
CI 1.01–6.08, P = 0.035). There was evidence of a nega-
tive association with previous hospitalizations (OR 0.290,
95% CI 0.120–0.690, P = 0.002), beginning of symptoms
abroad (OR 0.00, 0.00–0.57, P \ 0.005), indwelling for-
eign material (OR 0.110, 95% CI 0.020–0.370, P \ 0.001),
non-urological neoplasia (OR 0.100, 95% CI 0.000–0.970,
P = 0.0227), and previous treatment with a cephalosporin
(OR 0.160, 95% CI 0.060-0.490, P \ 0.001).
Resistance of ESBL-producing E. coli to other
antibiotics
The rates of resistance to antimicrobial agents in E. coli
urinary isolates are shown in Table 3. The rates of cipro-
floxacin resistance among the community-acquired UTI
were 84.8% and 77.3% in the healthcare-associated group.
The corresponding values for amoxicillin–clavulanic acid
were 69.6 and 77.3%, for piperacillin–tazobactam 25.3 and
27.3%, for trimethoprim–sulfamethoxazole 75.9 and
75.0%, for nitrofurantoin 15.4 and 33.3%, and for fosfo-
mycin 0 and 0%, respectively. The resistance rates for the
different antimicrobial agents did not differ among groups
with community-acquired versus healthcare-associated
isolates (all P [ 0.05).
Outcome
The outcome of 123 patients with ESBL-producing E. coli
urinary isolates is shown in Table 4. The median time of
follow up was 166 days (IQR 26-490). Nine patients died,
one thereof attributable to infection. All deaths occurred in
the healthcare-associated group, and, also, rehospitalization
rates were higher in the healthcare-associated group. New
infection rates were not significantly different between the
two groups.
Discussion
We retrospectively assessed the resistance rates of
ESBL-producing E. coli urinary isolates at our tertiary
referral center and characterized the corresponding
patients with resistant isolates. Within a 3-year period,
123 patients with UTI were followed, 79 (64.2%) with
community-acquired and 44 (35.8%) with healthcare-
associated ESBL-producing E. coli isolates. Patients
with community-acquired isolates were more likely to
be women (P = 0.035), presenting with acute uncom-
plicated UTI (P \ 0.001). Risk factors for community-
acquired isolates were female sex and recurrent UTI.
Rates of resistance to most currently used antimicro-
bial agents were high, and did not differ between
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community-acquired versus healthcare-associated ESBL-
producing E. coli isolates.
In recent years, several studies showed that multiresis-
tant pathogens like ESBL-producing E. coli are responsible
not only for healthcare-associated [20] but also for com-
munity-acquired UTI [8, 9, 11–14, 21]. We observed a
similar epidemiology at our institution (Fig. 1), although
Switzerland is still regarded as a country with a low
Table 2 Univariate analyses of
risk factors for community-
acquired UTIs with ESBL-
producing E. coli
OR, odds ratio, CI confidence
interval, UTI urinary tract
infection
Variables, n (%) Total UTI Community-acquired
UTI
OR (95% CI) P-value
Number of patients 123 (100) 79 (100)
Age \ 50 years 65 (52.8) 44 (55.7) 1.37 (0.620–3.08) 0.453
Female gender 90 (73.2) 63 (79.7) 2.46 (1.01–6.08) 0.035
Hospital stay in the previous year 68 (55.7) 36 (45.6) 0.290 (0.120–0.69) 0.002
Repeated outpatient visits 82 (66.7) 51 (64.6) 0.770 (0.310–1.80) 0.554
Beginning of symptoms abroad 5 (4.1) 0 (0) 0.00 (0.00-0.570) 0.005
Asymptomatic bacteriuria 49 (39.8) 24 (30.4) 0.330 (0.14-0.76) 0.007
Uncomplicated UTI 29 (23.6) 26 (32.9) 6.62 (1.83–36.5) \0.001
Uncomplicated pyelonephritis 8 (6.5) 5 (6.3) 0.92 (0.17–6.25) 1.000
Complicated UTI 37 (30.1) 24 (30.4) 1.04 (0.44–2.56) 1.000
Anomaly of the urinary tract 60 (46.8) 32 (40.5) 0.390 (0.170–0.89) 0.016
Previous urological operation 41 (33.3) 23 (29.1) 0.600 (0.260–1.39) 0.232
Foreign material in the urinary
tract
19 (15.4) 4 (5.1) 0.110 (0.020–0.370) \0.001
Recurrent UTI 36 (29.2) 29 (36.7) 3.04 (1.14-9.14) 0.022
Non-urological neoplasia 6 (4.9) 1 (1.3) 0.100 (0.000–0.970) 0.023
Diabetes mellitus 16 (13.0) 8 (10.1) 0.510 (0.150-2.70) 0.264
Immunosuppression 23 (18.7) 14 (17.7) 0.840 (0.300–2.53) 0.810
Antibiotic use in the previous year,
any
80 (65.0) 52 (65.8) 1.10 (0.470–2.54) 0.845
Cephalosporins 21 (17.1) 6 (7.6) 0.160 (0.060–0.490) \0.001
Quinolones 56 (45.5) 38 (48.1) 1.54 (0.69–3.53) 0.265
Table 3 Rates of resistance in
ESBL-producing E. coli
isolates, stratified by the mode
of acquisition of UTI
UTI urinary tract infection
Antimicrobial agent Community-acquired UTI Healthcare-associated UTI P-value
Number of
isolates
analyzed, n (%)
Number of
isolates
resistant, n (%)
Number of
isolates
analyzed, n (%)
Number of
isolates
resistant, n (%)
Ampicillin 79 (100) 78 (98.7) 44 (100) 43 (97.7) 0.361
Amoxicillin–
clavulanic acid
79 (100) 55 (69.6) 44 (100) 34 (77.3) 0.526
Amikacin 68 (100) 6 (8.80) 37 (100) 1 (2.70) 0.417
Gentamycin 79 (100) 40 (51.3) 44 (100) 26 (59.1) 0.453
Tobramycin 77 (100) 53 (68.8) 42 (100) 28 (66.7) 0.839
Piperacillin–
tazobactam
79 (100) 20 (25.3) 44 (100) 12 (27.3) 0.834
Trimethoprim–
sulfamethoxazole
79 (100) 60 (75.9) 44 (100) 33 (75.0) 0.828
Ciprofloxacin 79 (100) 6 (84.8) 44 (100) 34 (77.3) 0.318
Norfloxacin 62 (100) 52 (83.9) 34 (100) 29 (85.3) 1.000
Ertapenem 50 (100) 1 (2.0) 24 (100) 0 (0) 1.000
Meropenem 74 (100) 2 (2.7) 40 (100) 1 (2.5) 1.000
Impipenem 75 (100) 2 (2.7) 42 (100) 0 (0) 0.536
Fosfomycin 23 (100) 0 (0) 11 (100) 0 (0) –
Nitrofurantoin 26 (100) 4 (15.4) 12 (100) 4 (33.3) 0.232
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prevalence of ESBL production [22] and low antibiotic use.
The results of our study confirm published risk factors for
community-acquired UTI with ESBL-producing E. coli,
namely, recurrent UTI and female sex being the most
commonly reported factors [9, 11–13, 15]. Other studies
found associations with the use of quinolones [9, 12, 15],
aminopenicillins [9], penicillins [12], cephalosporins [9],
b-lactam antibiotics [13], diabetes mellitus [15], and
prostatic disease [13, 15], whereas we did not observe these
factors. In contrast, we found negative associations for
community-acquired ESBL-producing E. coli with the use
of cephalosporins, previous hospital stay, beginning of
symptoms abroad, non-urological malignancies, anomaly
of the urinary tract, and foreign material in the urinary
tract. Differences between our results and other reports are
explained by the different study designs. Previous studies
assessed risk factors for community-acquired ESBL-posi-
tivity by comparing outpatients with ESBL-producing
E. coli-positive urinary samples with control patients with
non-ESBL-producing E. coli isolates [9, 11–13, 15],
whereas we compared exclusively the isolates of ESBL-
producing E. coli stratified by the location of acquisition of
UTI, i.e., community versus healthcare infection.
One may expect that community-acquired E. coli isolates
would express less resistance to antimicrobial agents than
healthcare-associated isolates, which would translate into
better treatment outcome. However, epidemiologic results
indicate that ESBL-producing E. coli UTI is rather com-
munity-acquired—possibly a food-borne disease—and
probably less as a consequence of antibiotic pressure in
healthcare settings, nosocomial transmission, or repeated
antibiotic therapy of outpatients with urological morbidity,
particularly obstruction of the urinary tract [4]. E. coli that
produce CTX-M b-lactamases seem to be true community
ESBL-producers with a different epidemiology than TEM-
or SHV-derived ESBL, which are typically healthcare- or
hospital-associated [23]. We, therefore, compared patient
characteristics, the clinical course of UTI, and susceptibility
patterns of ESBL-producing E. coli in community-acquired
and healthcare-associated isolates, whereas previous studies
were content with comparing antibiotic resistance rates
exclusively in ESBL-positive and ESBL-negative isolates
[9, 13]. We found that neither resistance nor cure rates were
different in community-acquired versus healthcare-associ-
ated ESBL-producing E. coli UTI. The resistance rates of
community-acquired ESBL-producing E. coli for cephalo-
sporins, trimethoprim–sulfamethoxazole, ciprofloxacin,
amoxicillin–clavulanic acid, carbapenems, and gentamycin
in our study were similar to those reported by a tertiary
referral center in Turkey [13]. ESBL-producing E. coli
exhibited a 100% susceptibility to fosfomycin, but the
resistance rates of nitrofurantoin were higher at our insti-
tution than those reported by other studies [9, 13, 21]. This
is particularly worrisome because treatment options for
ESBL-producing E. coli are limited, but when exclusively
considering isolates from acute uncomplicated UTI, no
resistance for nitrofurantoin was detected.
Previous studies on community-acquired UTI did often
not account for risk factors for antibiotic resistance, such as
home intravenous therapy, specialized wound care at
home, hemodialysis, antineoplastic chemotherapy, and
residence in a nursing home or long-term facility. By using
the criteria of Friedmann et al. [17], we had a standardized
tool to separate community-acquired from healthcare-
associated cases. Nevertheless, the differentiation of com-
munity versus healthcare versus nosocomial infection may
be particularly difficult in comorbid or multimorbid
patients with symptomatic or asymptomatic bacteriuria
who have frequent contacts with hospital-based outpatient
clinics or other healthcare institutions. Also, some other
limitations of our (and other studies) should be noted.
Demographic and clinical data were retrieved from patient
charts, and available information on outpatients is usually
not as detailed as for hospitalized patients, thus, potentially
leading to a measurement bias. We tried to preclude this
bias by using a structured questionnaire. Antimicrobial
Table 4 Outcome of 123 individuals with extended-spectrum b-
lactamase-producing E. coli in urinary samples, stratified by mode of
acquisition of UTI
Outcome Community-
acquired UTI,
n = 79 (%)
Healthcare-
associated UTI,
n = 44 (%)
P-value
Death, n (%) 0 (0) 9 (20.5) \0.001
Readmission,
n (%)
23 (29.1) 24 (54.5) 0.007
Relapse or
reinfection
31 (39.2) 19 (43.2) 0.700
Fig. 1 Acute uncomplicated urinary tract infections (UTIs) with
community-acquired Escherichia coli extended-spectrum b-lactamas-
es (ESBLs) treated at the University Hospital of Zurich, Switzerland
338 S. Meier et al.
123
therapy for UTI in outpatients is usually started empiri-
cally, and urinary cultures are only performed if patients do
not respond to treatment or have complicated or recurrent
UTI [24]. Thus, a selection bias may have been introduced
by overestimating the resistance rates in the community.
However, we believe that this was a minor source of bias,
since the resistance rates of community-acquired and
healthcare-associated ESBL-producing E. coli isolates
were virtually the same. The results of resistance tests to
fosfomycin and nitrofurantoin deserve careful evaluation,
because routine testing for these antimicrobial agents in
ESBL-positive urinary samples was introduced at our
institution only in 2009. The retrospective design of our
study may complicate outcome analyses, especially in
patients with community-acquired isolates, and general-
ization may be diminished because our data were collected
at a single hospital.
Until recently, local and many other guidelines recom-
mended the use of a 3-day course of trimethoprim–sulfa-
methoxazole or norfloxacin for acute uncomplicated UTI.
Because of the increasing resistance rate of these sub-
stances, the emergence of community-acquired ESBL-
producing E. coli, and because of the high rates of
resistance to other antimicrobials, these recommendations
can no longer be substantiated. Treatment with amoxicil-
lin–clavulanic acid, as proposed by Rodrı´guez-Ban˜o et al.
[9], does not seem to be applicable because of high resis-
tance rates in non-ESBL- and ESBL-producing E. coli, and
ertapenem, which would be suited for an outpatient intra-
venous therapy, should be used with caution in order to
prevent further spread of carbapenemase-producing
Enterobacteriaceae [25]. The need for a revision of
empirical treatment guidelines for UTIs is also substanti-
ated by the inappropriate high use of quinolones—quino-
lones themselves being a risk factor for the development of
ESBL. As a consequence, the Infectious Disease Society of
America (ISDA) and the European Society of Clinical
Microbiology and Infectious Disease (ESCMID) issued on
March 1, 2011 new treatment guidelines for UTIs consid-
ering a 5-day course of nitrofurantoin or a single dose of
fosfomycin, which are appropriate choices for the treat-
ment of acute uncomplicated urinary tract infections [26].
The use of trimethoprim–sulfamethoxazole is discouraged
in case resistance prevalence would exceed 20%, and the
use of quinolones and b-lactams for the treatment of acute
uncomplicated cystitis is no longer recommended.
In conclusion, we found an increasing prevalence of
ESBL-producing E. coli in community-acquired UTI.
These isolates showed high resistance rates for b-lactam
antibiotics, quinolones, and trimethoprim–sulfamethoxa-
zole—whereas the susceptibility to nitrofurantoin and
fosfomycin was excellent. Therefore, these antimicrobial
agents appear to be the empirical treatment of choice for
community-acquired UTI at present. However, an
increasing use of these substances may also result in anti-
biotic resistance, and, thus, only prudent use of all anti-
microbials may prevent selection pressure and avoid
clinical situations with no further treatment options.
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